Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARD2: ESK-001 in Moderate to Severe Plaque Psoriasis
2023-508959-39-00Phase 3Completed
- Sponsor
- Alumis Inc.
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of envudeucitinib in plaque psoriasis (3 arms), sponsored by Alumis Inc. Started Jan 2025; status: completed.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-508959-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508959-39-00.